SerpApi.Org
- Repligen (RGEN) and BioLife Solutions (BLFS) have entered into a definitive agreement under which Repligen will acquire BioLife for a total enterprise value of ~$1.5B, comprised of 64% in Repligen common stock and 36% in cash.
- BioLife stockholders are to receive cash and Repligen (RGEN) common stock at a value of $31.00 per share, representing a total enterprise value of ~$1.5B.
- Compelling financially, the transaction is expected to be accretive to Repligen’s top-line growth, adjusted margins, and adjusted earnings per share by at least 5 cents in year one and at least 25 cents in year two, the company said.
- Repligen reports preliminary second quarter reported revenue growth of approximately 12% or 13% organic; BioLife reports preliminary second quarter revenue growth of ~21% year-over-year.
- The deal fast-tracks Repligen’s customer solution offering in the high-growth cell therapy market by adding BioLife’s differentiated, high-margin recurring revenue business, according to the statement.
More on BioLife Solutions, Repligen
- Repligen Corporation (RGEN) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow
- Repligen Corporation (RGEN) Presents at 46th Annual William Blair Growth Stock Conference Transcript
- Repligen Has A Cleaner Recovery Angle, But With High Valuation
- BioLife is said to have drawn takeover interest from Repligen
- Biolife outlines 2026 revenue of $112.5M-$115M while targeting full-year GAAP net income
